Advertisement
Screener

PRECIGEN, INC. (PGEN) Executive Pay versus Performance: Pay versus Performance

PRECIGEN, INC. Pay versus Performance

The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.

  • 2025-12-31: PEO Helen Sabzevari; PEO total compensation $5.35M; PEO compensation actually paid $18.57M; Other NEO average total compensation $1.43M.
  • 2024-12-31: PEO Helen Sabzevari; PEO total compensation $5.43M; PEO compensation actually paid $4.61M; Other NEO average total compensation $1.31M.
  • 2023-12-31: PEO Helen Sabzevari; PEO total compensation $3.72M; PEO compensation actually paid $3.73M; Other NEO average total compensation $1.03M.
  • 2022-12-31: PEO Helen Sabzevari; PEO total compensation $3.50M; PEO compensation actually paid -$1.09M; Other NEO average total compensation $892.36K.
Fiscal year endPEOPEO total compensationPEO compensation actually paidOther NEO average total compensationOther NEO average compensation actually paidTotal shareholder returnPeer group total shareholder returnNet incomeCompany-selected measureProxy filed
2025-12-31Helen Sabzevari$5.35M$18.57M$1.43M$4.19M$40.98$124.75-$250.60M2026-04-30
2024-12-31Helen Sabzevari$5.43M$4.61M$1.31M$1.06M$20.44$113.80-$126.20M2026-04-30
2023-12-31Helen Sabzevari$3.72M$3.73M$1.03M$1.04M$24.45$115.40-$95.90M2026-04-30
2022-12-31Helen Sabzevari$3.50M-$1.09M$892.36K$601.34K$27.74$111.20$28.30M2026-04-30
2021-12-31Helen Sabzevari$2.52M-$16.11M$611.02K$230.40K$67.70$124.80-$92.20M2026-04-30
2024-12-31Helen Sabzevari$5.43M$4.61M$1.31M$1.06M$20.44$113.80-$126.20M2025-05-16
2023-12-31Helen Sabzevari$3.72M$3.73M$1.03M$1.04M$24.45$115.40-$95.90M2025-05-16
2022-12-31Helen Sabzevari$3.50M-$1.09M$892.36K$601.34K$27.74$111.20$28.30M2025-05-16
2021-12-31Helen Sabzevari$2.52M-$16.11M$611.02K$230.40K$67.70$124.80-$92.20M2025-05-16
2020-12-31Helen Sabzevari$20.41M$41.48M$1.17M$1.74M$186.13$125.60-$170.50M2025-05-16
2023-12-31Helen Sabzevari$3.72M$3.73M$1.03M$1.04M$24.45$118.87-$95.90M2024-05-28
2022-12-31$3.50M-$1.09M$892.36K$601.34K$27.74$113.65$28.30M2024-05-28
2021-12-31$2.52M-$16.11M$611.02K$230.40K$67.70$126.45-$92.20M2024-05-28
2020-12-31$20.41M$41.48M$1.17M$1.74M$186.13$126.42-$170.50M2024-05-28
2022-12-31Helen Sabzevari$3.50M-$1.09M$892.36K$601.34K$27.74$113.65$28.30M2023-04-25
2021-12-31$2.52M-$16.11M$611.02K$230.40K$67.70$126.45-$92.20M2023-04-25
2020-12-31$20.41M$41.48M$1.17M$1.74M$186.13$126.42-$170.50M2023-04-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
NewAmsterdam Pharma Co N.V. (NAMS)$2.719B-15.37
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Immunome Inc. (IMNM)United States$2.538B-9.45
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
uniQure N.V. (QURE)$2.416B-4.93
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67